Sofie Seghers | Oncology | Best Researcher Award

Warning: Undefined variable $insensitive in /home/u224081662/domains/ on line 201

Warning: Undefined variable $insensitive in /home/u224081662/domains/ on line 202

Mr. Sofie Seghers | Oncology | Best Researcher Award

University of Antwerp, Belgium

Author Profile

Early Academic Pursuits:

Sofie Hilda Antoon Marcelle Seghers commenced her academic journey at the University of Antwerp, where she laid the foundation for her illustrious career in medicine. Graduating with distinction, she obtained her Bachelor of Medicine and later pursued a Master of Medicine, excelling in both programs. Her dedication and aptitude for medical studies were evident from the outset, setting the stage for her future endeavors.

Professional Endeavors:

Driven by a passion for clinical oncology, Sofie embarked on a journey of professional growth and specialization. Her clinical experience spans various esteemed institutions, including AZ Klina, UZA, and ZNA Stuivenberg, where she honed her skills as a Clinical Oncology Fellow. This period of hands-on training equipped her with invaluable expertise, preparing her for the challenges ahead.

Contributions and Research Focus:

Sofie's research focus lies at the intersection of clinical applications and innovative methodologies in oncology. As a Ph.D. student at the University of Antwerp, her work centers on the utilization of patient-derived organoids in the treatment of solid tumors. Her contributions to the field have garnered widespread attention, with several publications highlighting her pioneering endeavors.

Accolades and Recognition:

Sofie's commitment to excellence has been acknowledged through numerous accolades and honors. Notably, she was recognized as a laureate for scientific research, a testament to her academic prowess and dedication to advancing medical knowledge. Her participation in esteemed scientific societies further underscores her standing as a respected figure within the medical community.

Impact and Influence:

Through her research and clinical practice, Sofie has made a significant impact on the field of oncology. Her contributions to patient-derived tumor organoids and immediate hypersensitivity reactions to antineoplastic agents have enriched our understanding of cancer treatment modalities. Moreover, her involvement in international conferences and symposiums has facilitated the dissemination of critical findings, shaping the future of oncological care.

Legacy and Future Contributions:

As Sofie continues to pursue her Ph.D. and engage in groundbreaking research, her legacy as a trailblazer in oncology is already well-established. Her manuscripts in preparation promise to further expand the frontiers of knowledge in metastatic solid tumor assessment, reaffirming her commitment to advancing medical science. With her passion, expertise, and determination, Sofie Seghers is poised to leave an indelible mark on the field of oncology for years to come.


A total of  41 citations for his publications, demonstrating the impact and recognition of his research within the academic community.

  • Citations            41
  • h-index              1
  • i10-index           1

Notable Publications 

The association between type of endocrine therapy and development of estrogen receptor-1 mutation (s) in patients with hormone-sensitive advanced breast cancer: a systematic …
O Najim, S Seghers, L Sergoynne, H Van Gaver, K Papadimitriou, ...
(40) 2019

Immediate hypersensitivity reactions to antineoplastic agents–A practical guide for the oncologist
S Seghers, LA Teuwen, M Beyens, D De Blick, V Sabato, DG Ebo, ...
(1) 2023

A Systematic Review of Patient-derived Tumor Organoids Generation from Malignant Effusions
S Seghers, M Le Compte, JMH Hendriks, P Van Schil, A Janssens, ...

610P Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding …
S Seghers, P Mando, CJL Tan, M Eid, AS Jayraj, LAMN Teuwen, J Young, ...

611P ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
P Mando, MS Faisal, K Jatwani, S Seghers, J Young, LAMN Teuwen, ...